Evidence map›Paper›PMID 40302540›Full record

ArticleJournal of medical virology2025

Disease Burden of RSV Infection in Adult Patients in Comparison to Influenza Virus Infection.

Georgii Trifonov, Erik Büscher, David Fistera, Clemens Kill, Joachim Risse, Christian Taube, Daniel Todt, Ulf Dittmer, Carina Elsner

Abstract readComparative Study
In one paragraph

Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Georgii TrifonovInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Erik BüscherDepartment of Pulmonary Medicine, University Medicine Essen-Ruhrlandklinik, Essen, Germany.
David FisteraCenter of Emergency Medicine, University Hospital Essen, Essen, Germany.
Clemens KillCenter of Emergency Medicine, University Hospital Essen, Essen, Germany.
Joachim RisseCenter of Emergency Medicine, University Hospital Essen, Essen, Germany.
Christian TaubeDepartment of Pulmonary Medicine, University Medicine Essen-Ruhrlandklinik, Essen, Germany.
Daniel TodtDepartment of Translational and Computational Infection Research, Ruhr University Bochum, Bochum, Germany.
Ulf DittmerInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Carina ElsnerInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0001-6590-8413

Funding

This study was supported by Bundesministerium für Bildung und Forschung and Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen.
6 · The paper itself

Abstract

Respiratory Syncytial Virus (RSV) is well known for its impact on children, but its burden in adults remains underexplored, partly due to limited PCR testing before the COVID-19 pandemic. In this study, the medical burden of RSV infections in adults was retrospectively investigated using 6-year longitudinal data from a university hospital in North Rhine-Westphalia, Germany. Outcomes of 380 PCR-confirmed RSV cases were compared with 1088 influenza A/B cases from 2018 to 2023, stratified by age groups ( < 60 and ≥ 60 years). Among RSV cases, 59.7% required hospitalization, of which 22.9% needed oxygen supply. In the whole group hospitalization rates were comparable between RSV and influenza cases, but oxygen supply was more frequent in influenza infections. However, in patients aged ≥ 60 years, no significant differences were observed in hospitalization, oxygen supply, or fatal outcomes between RSV and influenza, indicating a comparable disease burden for both viruses in this group. These findings highlight the significant clinical impact of RSV in adults, particularly those aged ≥ 60 years, paralleling that of influenza. Given influenza's established pathogenic reputation, this underscores the importance of targeted vaccination strategies against RSV, especially for high-risk age groups.

Indexed as

Cost of IllnessInfluenza, HumanRespiratory Syncytial Virus InfectionsAdolescentAdultAgedAged, 80 and overCOVID-19FemaleGermanyHospitalizationHumansInfluenza A virusLongitudinal StudiesMaleMiddle Agedclinical studyinfluenza virusrespiratory syncytial virusRSVvaccine

Identifiers

PMID40302540
PMCPMC12041907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.